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Background: The liver-specific glucokinase knockout (gckw/–) mouse experiences long-term hyperglycemia and
insulin resistance. This study was designed to evaluate the functional and structural changes in the myocardium
of 60 week-old gckw/– mice, and to investigate the effect of rosiglitazone on the myocardium in this model.
Methods: 60 week-old gckw/– mice were randomly divided into 3 groups: gckw/–, gckw/– mice treated with insulin
(1 U/kg) and gckw/– mice treated with rosiglitazone (18 mg/kg). Insulin or rosiglitazone treatment was for 4 weeks.
Gckw/w litermates were used as controls. Echocardiography, electrocardiogram, biochemical, histopathological,
ultrastructural, real time PCR and Western blot studies were performed to examine for structural and functional
changes.
Results: Long-term liver-specific gck knockout in mice elicits hyperglycaemia and insulin resistance. Compared to
age matched gckw/w mice, 60 week-old gckw/– mice showed decreased LV internal dimension, increased posterior
wall thickness, lengthened PR and QRS intervals, up-regulated MLC2 protein expression, decreased SOD activity,
increased MDA levels and up-regulated Cyba mRNA. Morphological studies revealed that there was an increase in
the amount of PAS and Masson positively stained material, as did the number and proportion of the cell occupied
by mitochondria in the gckw/– mice. Western blot analysis revealed that the levels of the insulin receptor, Akt,
phosphorylated AMPK beta and phosphorylated ACC were reduced in gckw/– mice. These effects were partly
attenuated or ablated by treatment with rosiglitazone.
Conclusions: Our results indicate that changes in the myocardium occur in the liver-specific glucokinase knockout
mouse and suggest that reduced glucokinase expression in the liver may induce diabetic cardiomyopathy by up
regulating NADPH oxidase and down regulating insulin receptor and p-AMPK protein levels. Rosiglitazone treatment
may protect against diabetic cardiomyopathy by altering the levels of a set of proteins involved in cardiac damage.
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Diabetic cardiomyopathy (DCM) is defined as structural
and functional changes in the myocardium, which are
independent of hypertension, chronic artery disease or
any other known cardiac diseases, and are caused by
metabolic and cellular abnormalities induced by diabetes
mellitus (DM). One of the most important structural
hallmarks of DCM is cardiac hypertrophy [1,2]. Hyper-
glycemia has been viewed as the pivotal pathogenetic
factor for the development of DCM. In fact, it can cause
abnormalities at the cardiac myocyte level, eventually
leading to functional and structural abnormalities, in-
cluding systolic and diastolic dysfunction, as well as car-
diac hypertrophy and myocardial fibrosis [3]. However,
other factors seem to be involved in the evolution of the
disease, including hyperinsulinemia, insulin resistance,
oxidative stress, inflammation, endothelial dysfunction
and apoptosis [1,2,4]. Animal models have been used to
study the mechanisms underlying DCM [5-8]. In some
animal models of DCM, drug treatment, or the effects of
genetic mutation often leads to obesity and diabetes. All
of these models have limitations and none are a perfect
phenocopy of the human condition [9].
Maturity-onset diabetes of the young (MODY) is a clin-
ically heterogeneous group of disorders and accounts for
about 2%–5% of all diabetic patients [10]. To date, five
proteins have been identified whose genetic absence
or impairment causes MODY, the enzyme glucokinase
(GCK/MODY2) and four transcription factors: hepatocyte
nuclear factor (HNF) 4α/MODY1, HNF-1α/MODY3, in-
sulin promoter factor 1/MODY4 and HNF-1β/MODY5.
MODY2 is one of the most prevalent subtypes of MODY
and is associated with mutations in the glucokinase gene
on Chromosome 7p and is characterized by chronic mild
hyperglycemia, with an onset usually before the age of 25
[11,12]. Little data is available on MODY2, as only a few
mouse models have been developed [10,13,14]. Bali et al.
[12] used homologous recombination in mouse embryonic
stem cells to assess the effects of disrupting GCK function
in both β-cells and hepatocytes as an animal model for
MODY2. A liver-specific glucokinase knockout mouse has
been constructed as a model for the liver-specific role of
glucokinase in MODY2, independent of its function in
regulating insulin secretion in pancreatic β-cells. Liver-
specific glucokinase knockout mice were generated using
the Cre-loxP gene targeting strategy, and the primary ef-
fects of the deletion of the gene have been evaluated [15].
The nuclear transcription factor peroxisome prolifera-
tor activated receptor γ (PPARγ) is a key regulator in ad-
ipogenesis. Thiazolidinediones, agonists of PPARγ, are
an established and effective treatment for patients with
type 2 diabetes [16]. Recently, there has been some con-
troversy regarding an increase in cardiovascular events,
including myocardial infarction and congestive heartfailure, in humans with the use of the PPARγ agonist,
rosiglitazone [17,18].
The aim of this study was to investigate the functional
and structural changes in the myocardium that result
from long-term reduced liver gck expression in our
mouse liver-specific gckw/– MODY2 model and to deter-
mine whether rosiglitazone or insulin can reverse these
changes in these mice.
Methods
Animals
A protocol for these experiments, following the “Guide-
lines for Animal Experiments”, was approved by the
Peking University Health Science Center. Liver-specific
gck knockout mice were previously generated by our lab
[15]. Liver-specific gck knockout mice (gckw/–) were ran-
domly divided into 3 groups: untreated (gckw/–, n = 9),
gckw/– treated with insulin (gckw/– + Ins, n = 9) and
gckw/– treated with rosiglitazone (gckw/– + RSG, n = 9).
Wild-type littermates (gckw/w, n = 9) were used as con-
trols. Insulin (1 U/kg/day) was administrated to the gckw/–
mice by subcutaneous injection for 4 weeks (gckw/– + Ins).
Rosiglitazone (18 mg/kg/day) was administrated to the
gckw/– mice by gavage for 4 weeks (gckw/– + RSG).
Assay of biochemistry parameters
An intraperitoneal glucose tolerance test (ipGTT) was
performed in each group by intraperitoneal injection of a
20% glucose solution at a dose of 2 g/kg. Tail vein blood
glucose levels were measured using a Roche blood glucose
monitor (Glucotrend 2, Roche, Germany) in samples
taken immediately before the glucose injection and at
30, 60, and 120 minutes after. Fasting insulin levels were
quantified using a commercially available radioimmuno-
assay kit (China Institute of Atomic Energy, Beijing,
China). Insulin sensitivity and β-cell capability of individ-
ual animals was evaluated using the homeostasis model
assessment (HOMA) index [19]. The formula used was
the following:
HOMA−IR½  ¼ fasting serum glucose mmol=Lð Þ
 fasting serum insulin mIU=Lð Þ=22:5:
HOMA−β−cell½  ¼ 20 fasting serum insulin mIU=Lð Þ=
fasting serum glucose mmol=Lð Þ−3:5ð Þ:
Echocardiography
Transthoracic echocardiography was performed on pento-
barbital anesthetized mice at rest using a high-resolution
imaging system for small animals (Vevo 770, VisualSonics,
Toronto, Canada), equipped with a high-frequent ultra-
sound probe (RMV-707B). Parasternal long-axis and
short-axis views were acquired. Left ventricular (LV) di-
mensions and wall thicknesses were determined from
parasternal short axis M-mode images. Ejection fraction
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the Vevo770 software. The final data represent the aver-
aged values of 3–6 cardiac cycles.
Electrocardiographic recordings
Surface electrocardiographic (ECG) recordings were ob-
tained from conscious mice. For analysis of ECGs, the
onsets and offsets of the P, Q, R, S, and T waves were
determined by measuring the earliest (onset) and the lat-
est (offset) times from lead II.
Western blot
Sodium dodecyl sulfate-polyacrylamidegel electrophor-
esis (SDS-PAGE) and Western blot to measure myo-
cardium myosin light chain (MLC2), insulin receptor
β (IRβ), Akt, adenosine 5′-monophosphate (AMP)-
activated protein kinase alpha (AMPKα), p-AMPKα,
AMPKβ1/2, p-AMPKβ1, acetyl-CoA carboxylase (ACC)
and p-ACC were performed. Heart tissue was homoge-
nized and protein was quantified using the Bradford
method. Sixty micrograms of protein was separated on
SDS-PAGE. Separated proteins were transferred by elec-
troelution onto PVDF paper (Millipore, Billerica, USA).
Blots were probed with rabbit antibodies to insulin
receptor β, Akt, AMPKα, Phospho-AMPKα (Thr172),
AMPKβ1/2, Phospho-AMPKβ1 (Ser108), ACC and
Phospho-ACC (Ser79). All antibodies were obtained from
Cell Signaling Technology (Beverly, MA, USA) and used
at 1:1000 dilution with incubation overnight at 4°C. Anti-
mouse MLC2 antibody was procured from Santa Cruz
Biotechnology (Dallas, USA). Antibody binding was detected
after incubation with appropriate secondary antibodies con-
jugated with HRP, with the membrane-bound antibodies vi-
sualized by luminal chemiluminescence ChemiDoc XRS
(Bio-Rad, Hercules, CA, USA).
Reverse transcription and real-time PCR
Heart tissues were homogenized and total RNA was iso-
lated using Trizol LS reagent (Invitrogen, Carlsbad,
USA) according to the manufacturer’s instruction. Am-
plifications were performed with the BIO-RAD Miniop-
ticon TM Real-Time PCR Detection system CFB-3120
using iQTM SYBR Green Supermix 170–8880 (Bio-Rad)
with the primers listed in Table 1. Amplifications were
performed using the following conditions: initial denatur-
ation at 95°C for 10 min followed by 39 cycles performed
at 95°C for 15 s and 67°C for 1 min. Transcription levels
were normalized to those of beta actin.Table 1 List of primers used in this study
Forward primer Reverse primer
Cyba CATGTGGGCCAACGAACAG CACTGTGTGAAACGTCCAGCAGTA
Cybb TGATCCTGCTGCCAGTGTGTC GTGAGGTTCCTGTCCAGTTGTCTTC
Fibronectin 1 GCTTTGGCAGTGGTCATTTCAG ATTCCCGAGGCATGTGCAGPAS staining
Prepared heart slides were stained with periodic acid-
Schiff ’s reagent (PAS) for glycogen and evaluated by
light microscopy. The glycogen content of the myocar-
dial tissue sections was expressed as the relative area of
positive PAS-stained tissue (purple red-stained glycogen)
to the total tissue area using Image-Pro Plus 6 (Media
Cybernetics, Rockville, USA).
Masson staining
Mouse cardiac tissue was first fixed on Bouin’s fixative
and stained with Weigert’s hematoxylin and Biebrich
scarlet-acid fuchsin (Sigma, Milwaukee, USA), followed
by treatment with phosphomolybdic–phosphotungstic
acid solution (Sigma) and staining by methyl blue and
Mayer’s Hematoxylin and Eosin. The extent of fibrosis
in the myocardial tissue sections was quantified using
Image-Pro Plus 6 (Media Cybernetics, Rockville, USA)
as the relative area of positive stained area (blue–green
fibrosis) normalized to the total tissue area.
Electron microscopy
Samples were collected from freshly excised left ventricu-
lar myocardium and processed as described previously
[20]. The proportion of the cell volume occupied by mito-
chondrial (volume density) and the number of mitochon-
dria were analyzed in a blinded fashion by the point
counting method using Image-Pro Plus 6 (Media Cyber-
netics, Rockville, USA). Mitochondrial volume density was
quantified as the relative area of mitochondrial area nor-
malized to the total cell area.
SOD activity and MDA levels
Superoxide dismutase (SOD) activities and malondialde-
hyde (MDA) levels in the myocardial tissues and serum
were determined using commercially available kits (Nanjing
Jiancheng Bioengineering Institute, Nanjing, China).
Statistical analysis
Results are shown as means ± SD. Differences between
the control and experimental groups were evaluated by
one-way (ANOVA; SPSS 13.0 for Windows, SPSS Inc.,
Chicago, IL, USA). P values less than 0.05 were consid-
ered to be statistically significant.
Results
Effects of the liver-specific gck gene knockout on glucose
homeostasis and insulin resistance in mice
Fasting glucose and HOMA-IR levels were significantly
higher and HOMA-β-cell levels significantly lower in liver-
specific gck knockout mice (gckw/–) than in gckw/w mice
(Figure 1). In the gckw/–, treatment with rosiglitazone did
not change the fasting glucose and calculated HOMA-β-cell
levels, but did result in a significant decrease in both the
Figure 1 Effect of rosigitizone and insulin on fasting glucose (A), insulin (B), HOMA-IR (C) and HOMA-β-cell (D) levels in 60-week old
gckw/– mice. Glucose and insulin levels as well as calculated HOMA-IR and HOMA-β-cell levels are shown for 60-week old wild-type (gckw/w) and
liver-specific gck knockout (gckw/–) mice as well as gck knockout mice treated with insulin or rosigitizone for 4 weeks. n = 6 for all samples.
Asterisk (*) refers to statistical significance (P < 0.05) in comparisons with gckw/– mice, while #refers to comparisons with gckw/w mice.
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Figure 1). Glucose levels at 0, 30, 60, and 120 minutes after
glucose injection and the AUC were significantly higher
in the gckw/– than in the gckw/w mice (p < 0.05) (Figure 2).
Compared to the pre-treatment responses, rosiglitazone
treatment decreased the AUC and the impairment in the
glucose tolerance response in the gckw/– mice, but only
reached significance at the 60 and 120-minute time points
after glucose injection (p < 0.05) (Figure 2).Figure 2 Intra-peritoneal glucose tolerance tests (ipGTT) in 60-week o
curve of the ipGTT (AUC) (B) are shown. Glucose levels were measured at 0
gck knockout (gckw/–) mice as well as knockout mice treated with insulin o
statistical significance (P < 0.05) in comparisons with gckw/– mice, while # rLeft ventricle internal dimension and posterior wall
thickness is deteriorated in the liver-specific gck gene
knockout mouse
Doppler and M-mode images revealed that significant
echocardiographic changes are found in the gckw/– mice.
Left ventricle (LV) internal dimension during diastole
(LVID;d) and systole (LVID;s) were significantly decreased
in the gckw/– mice, compared to gckw/w mice. LVID;d sig-
nificantly increased after treatment with insulin orld liver-specific gck knockout mice. ipGTT (A) and areas under the
, 30, 60, 120 minutes after glucose injection in wild-type (gckw/w) and
r rosiglitazone for 4 weeks. n = 6 for all samples. Asterisk (*) refers to
efers to comparisons with gckw/w mice.
Table 3 ECG parameters in gckw/– and gckw/w mice (n = 6)
gckw/w gckw/– gckw/– + Ins gckw/– + RSG
Heart Rate(BPM) 613.9 ± 51.47 537.9 ± 65.6 592.6 ± 87.3 505.3 ± 39.9
P Duration(ms) 9.22 ± 1.64 14.82 ± 7.68 8.06 ± 1.96 10.82 ± 1.36
PR Interval(ms) 38.28 ± 2.31* 44.77 ± 7.46# 36.75 ± 6.29* 38.41 ± 0.67*
QRS Interval(ms) 8.54 ± 1.35** 13.35 ± 3.28## 8.37 ± 1.87* 9.77 ± 0.71*
QT Interval(ms) 18.06 ± 1.56 21.04 ± 2.28 16.98 ± 0.60 16.13 ± 1.89
QTc(ms) 58.10 ± 3.83 63.28 ± 10.73 53.36 ± 5.81 46.92 ± 6.97
Data are expressed as the mean ± standard. QTc, Corrected QT Interval.
QTc = QT/(RR/100)1/2. n = 3 for all samples. Asterisk (*) refers to statistical
significance (P < 0.05 for * and P < 0.005 for **) in comparisons with gckw/– mice,
while # refers to statistical significance (P < 0.05 for # and P < 0.005 for ##) in
comparisons with gckw/w mice.
Li et al. Cardiovascular Diabetology 2014, 13:24 Page 5 of 14
http://www.cardiab.com/content/13/1/24rosiglitazone. LV posterior wall thickness during diastole
(LVPW;d) and systole (LVPW;s) were significantly increased
in the gckw/– mice, compared to gckw/w mice. Changes in
the ejection fraction (%EF) and fraction of shortening (%FS)
were not statistically different in the gckw/– mice, compared
to gckw/w mice, however insulin or rosiglitazone treatment
yielded significant increases (p < 0.05,versus gckw/–) (Table 2).
PR and QRS intervals are lengthened in the liver-specific
gck knockout mouse
Surface ECG recordings showed significantly longer PR
intervals in the gckw/– mice versus gckw/w mice, as did
QRS intervals (Table 3). Treatment of gckw/– mice with in-
sulin or rosiglitazone significantly shortened both the PR
intervals and QRS intervals (p < 0.05, Table 3). Changes in
heart rates, P Duration, QT intervals, and corrected QT
(QTc) intervals were not statistically different among the
four groups.
Liver-specific gck gene knockout mice have increased
myocardium MLC2 protein levels
Myosin light chain 2 (MLC2) is expressed in the heart in
a restricted manner during development and has been
shown to play a key role in cardiogenesis [21]. We per-
formed Western blot analysis to measure the protein
levels of MLC2 and found that they were significantly
increased in the gckw/– mice, compared with the gckw/w
mice, and were restored to more normal levels with rosi-
glitazone or insulin treatment (p < 0.05, Figure 3).
Liver-specific gck gene knockout aggravates oxidative
stress in mouse serum and myocardium tissue
Our data showed a significant reduction in SOD activity
and an elevation of MDA levels in gckw/– mice, com-
pared to gckw/w mice, in serum and myocardium tissueTable 2 Echocardiographic measurements (M-mode) in
gckw/– and gckw/w mice (n = 3)
gckw/w gckw/– gckw/– + Ins gckw/– + RSG
LVID;d 2.55 ± 0.15* 2.06 ± 0.16# 2.54 ± 0.15* 2.50 ± 0.12*
LVPW;d 0.84 ± 0.10* 1.03 ± 0.06# 1.27 ± 0.10#* 1.08 ± 0.07#
LVID;s 1.15 ± 0.05* 0.84 ± 0.08# 0.86 ± 0.07* 0.89 ± 0.11*
LVPW;s 1.14 ± 0.14* 1.54 ± 0.17# 1.90 ± 0.09#* 1.74 ± 0.03#*
LVAW;d 0.93 ± 0.09 0.83 ± 0.21 1.19 ± 0.09#* 0.94 ± 0.06
LVAW;s 1.12 ± 0.42 1.48 ± 0.15 1.76 ± 0.05* 1.48 ± 0.39
%EF 86.87 ± 1.97 90.62 ± 2.31 94.08 ± 1.23* 93.23 ± 2.07*
%FS 54.49 ± 2.58 59.31 ± 3.52 66.19 ± 2.59#* 64.61 ± 4.01#*
Data are expressed as the mean ± standard. LVID;d, LV internal diameter in
diastole. LVPW;d, LV posterior wall thickness in diastole. LVID;s, LV internal
diameter in systole. LVPW;s, LV posterior wall thickness in systole. LVAW;d, LV
anterior wall thickness in diastole. LVAW;s, LV anterior wall thickness in systole.
EF, Ejection fraction. FS, Fractional shortening. n = 3 for all samples. Asterisk (*)
refers to statistical significance (P < 0.05 for *) in comparisons with gckw/– mice,
while # refers to statistical significance (P < 0.05 for #) in comparisons with
gckw/w mice.(Figure 4). Serum and myocardium SOD activities were
significantly increased after treatment with rosiglitazone
(p < 0.05), however only myocardium SOD activity was
significantly increased after treatment with insulin (p <
0.05). Myocardium MDA levels were significantly decreased
after treatment with rosiglitazone (p < 0.05), but not with
insulin. There was no significant difference after treatment
with rosiglitazone or insulin in serum MDA levels. As
shown in Figure 4E, the level of cytochrome b-245 alpha
(Cyba) mRNA in the myocardium of gckw/– mice was sig-
nificantly higher than that of gckw/w mice, and was normal-
ized by treatment with rosiglitazone or insulin (p < 0.05).
Cytochrome b-245 beta (Cybb) mRNA levels did not show
a significant change, whether untreated or when the mice
were treated with rosiglitazone or insulin.
Cardiac fibrosis was increased in the liver-specific gck
knockout mouse
Under the microscope, in gckw/w mice, the distribution of
collagen (Masson positive material) was almost uniform,
where the collagen fiber network among adjacent cells
was intact and had lower levels of collagen fiber content
(Figure 5). In the gckw/– mice, significantly increased levels
of myocardial collagen, which was broken and arranged in
a disordered collagen fiber network around the myocardial
cells, was observed (Figure 5). The relative content of colla-
gen or glycoproteins (PAS-positive material) in myocardial
tissue was measured and the results showed, compared
with gckw/w mice, that the myocardial collagen or glycopro-
teins content of gckw/– mice was significantly increa-
sed (p < 0.01), suggesting the accumulation of collagen and
glycoproteins in this mouse model. Compared with gckw/–
mice, the collagen and glycoprotein content in the rosiglita-
zone or insulin treated groups were decreased significantly
(p < 0.05), suggesting that both rosiglitazone and insulin
inhibit the accumulation of collagen and glycoproteins
(Figure 5). As shown in Figure 5D, the levels of fibronectin1
mRNA in the myocardium of the gckw/– mice was signifi-
cantly higher than in gckw/w mice and both rosiglitazone
and insulin restore levels to the wild-type levels (p < 0.05).
Figure 3 Quantification of the protein levels of myosin light chain 2 (MLC2) in 60-week old liver-specific gck knockout mice.
Representative Western blot images (A) and quantification of the MLC2 Western blots in heart homogenates (B) are shown for wild-type (gckw/w)
and gck knockout (gckw/–) mice as well as knockout mice treated with insulin or rosiglitazone for 4 weeks. n = 3 for all samples. Asterisk (*) refers
to statistical significance (P < 0.05) in comparisons with gckw/– mice, while # refers to comparisons with gckw/w mice.
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volume density and number
Mitochondrial structure and myocardial ultrastructure
were evaluated by electron microscopy. Cristae density
of the mitochondria was decreased in the gckw/– mice
(Figure 6A). Mitochondrial volume density (Figure 6B)
and number (Figure 6C) were increased in the gckw/–
mice, compared to gckw/w mice. These properties were
restored to wild-type levels by treatment with rosiglita-
zone or insulin (p < 0.05).
Liver-specific gck gene knockout impairs the levels of the
insulin receptor and Akt
The insulin signaling pathway plays important roles in the
pathogenesis of type 2 diabetes mellitus. Protein levels of
the insulin receptor and Akt were significantly down-
regulated in the gckw/– mice, compared with gckw/w mice
(Figure 7), and this change was reversed by treatment with
rosiglitazone (p < 0.05). No significant changes in the
levels of PI3K or mTOR proteins were observed (Figure 7).
These results indicate that the gckw/– mice show a signifi-
cant modulation of the insulin signaling pathway, which
might be linked to additional deleterious consequences for
the gckw/– mice.
Liver-specific gck gene knockout reduces AMPKβ and
ACC phosphorylation
Protein levels of p-AMPKβ1were significantly down regu-
lated in the gckw/– mice, compared with gckw/w mice
(p < 0.05, Figure 8). In addition, rosiglitazone and insulin
did not affect AMPKβ phosphorylation. p-AMPKα protein
levels did not change significantly when the gckw/– mice
were treated with rosiglitazone or insulin. To examine
whether AMPK regulates ACC phosphorylation in gckw/–
mice, we examined the protein levels of p-ACC. Surpris-
ingly, the level of p-ACC was dramatically lower in thegckw/– mice in comparison to gckw/w mice (p < 0.05). The
level of p-ACC was restored to wild-type levels by treat-
ment with rosiglitazone (p < 0.05), but not with insulin
(Figure 8).
Discussion
MODY2 in humans is characterized by mild but chronic
hyperglycemia, with some MODY2 patients displaying
peripheral insulin resistance, but diabetes-associated
macro- and micro-vascular complications, overweight,
and dyslipidemia are uncommon [22,23]. Patients can
usually manage their blood glucose levels by diet and ex-
ercise alone [11]. The liver-specific gck knockout mice
(gckw/–) appear normal at birth, with measurement of
plasma insulin, triglyceride, cholesterol, ALT, and AST
showing no difference compared with wild-type mice at
up to 6 weeks of age [15]. These parameter are similar
to those observed in MODY2 patients. Fasting blood
glucose levels in these mice increase with age and these
mice spontaneously develop hyperglycemia after 6 weeks
of age with impaired glucose tolerance and a decreased
accumulation of hepatic glycogen [15]. These mice how-
ever, do not exhibit signs of obesity with aging [15]. No
evidence of autoimmunity in the pancreatic islets is ex-
hibited by these knockout mice [15]. The gckw/– mouse,
thus, may serve as a model of human MODY2 diabetes
as it is associated with mild hyperglycemia and insulin
resistance without hypoinsulinemia. These mice (gckw/–
mice) were used to investigate the functional and struc-
tural changes in the myocardium that result from long-
term (60 weeks) reduced liver gck expression (yielding
mild hyperglycemia) followed by 4 weeks with or with-
out treatment with insulin or rosiglitazone.
Diabetic cardiomyopathy describes diabetes-associated
changes in myocardial structure and function. HOMA-
IR is based on the dynamic interaction between glucose
Figure 4 Oxidative stress in 60-week old liver-specific gck knockout mice. Serum and myocardium SOD activity (A and B), MDA levels (C
and D), and relative levels of mRNA for Cyba (E) and Cybb (F) in the myocardial are shown for wild-type (gckw/w) and gck knockout (gckw/–) mice
as well as knockout mice treated with insulin or rosiglitazone for 4 weeks. mRNA levels were determined by real-time PCR and corrected with
beta actin as an internal standard. n = 6 for all samples. Asterisk (*) refers to statistical significance (P < 0.05) in comparisons with gckw/– mice,
while # refers to comparisons with gckw/w mice.
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representation of insulin resistance when compared to
the gold standard reference, the euglycemic clamp [24].
In several studies, an association between diabetic car-
diomyopathy and HOMA-IR has been found. The
HOMA index is an independent determinant of LV dia-
stolic function [25]. Insulin resistance has been corre-
lated with increased left ventricular mass and risk of
heart failure [26]. In this study, we found that in gckw/–
mice both serum glucose levels and insulin resistance
were dramatically elevated compared with the control
group (gckw/w mice). It has been demonstrated that theimpairment of glucose homeostasis is able to affect the
severity of heart disease.
MLC2 is part of the myosin complex, a hexameric
complex of two heavy chains and four light chains, pre-
dominantly expressed in cardiac ventricle muscle [21].
The regulatory light chains of the myosin complex,
MLC2, can be phosphorylated leading to a conform-
ational change, which consequently affects muscle con-
traction [27]. Mutations in the human MLC2 gene have
been associated with hypertrophic cardiomyopathy and
lack of MLC2 in mice is embryonic lethal due to cardiac
dysfunction that results in heart failure, a massive
Figure 5 Cardiac fibrotic levels in 60-week old liver-specific gck knockout mice. Cardiac fibrosis levels were investigated in wild-type
(gckw/w) and gck knockout (gckw/–) mice as well as knockout mice treated with insulin or rosiglitazone for 4 weeks. Images of PAS and Masson staining
are shown in (A) with positive Masson IOD/area (B), and positive PAS IOD/area (C) shown. The relative amount of mRNA for fibronectin 1 in the myocardial,
which was determined by real-time PCR and corrected with beta actin as an internal standard, is shown in (D). n = 3 for all samples. Asterisk (*) refers to
statistical significance (P < 0.05 for * and P < 0.001For ***) in comparisons with gckw/– mice, while # refers to statistical significance (P < 0.005 for ## and
P < 0.001 for ###) in comparisons with gckw/w mice.
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myofibril assembly [21]. In this study, we found that in
gckw/– mice the level of MLC2 protein expression was
dramatically elevated compared with the control group
(gckw/w mice). Koka et al. [28] revealed a coordinated
down regulation of cytoskeletal contractile proteins such
as myosin heavy-chainα (αMHC), and an up-regulation of
MLC2 in diabetic mice, a result consistent with our re-
sults. The specific mechanism underlying these changes is
unclear and we hypothesized that an increase in MLC2
levels may lead to myocardial hypertrophy by interfering
with the assembly of myofibrils.In several studies, an association between diabetic car-
diomyopathy and cardiac hypertrophy, increased myo-
cardial stiffness and reduced chamber compliance has
been found [29]. Clinical studies have demonstrated that
diabetic cardiomyopathy is manifested with left ventricu-
lar hypertrophy associated with systolic/diastolic dys-
function and cardiac fibrosis in diabetic patients [30]. In
the present study, we observed cardiac hypertrophy
in the gckw/– mouse, which was observed as an increase
in the left ventricular wall thickness, a decrease of the
left ventricular internal dimension, longer PR and QRS
intervals, and increased myocardium MLC2 protein
Figure 6 Changes in mitochondrial ultrastructure in the hearts of 60-week old liver-specific gck knockout mice. Representative electron
micrographs (×12,000 or × 60,000) (A), stereological quantification of mitochondrial volume density (B), and mitochondrial number (C) of
wild-type (gckw/w) and gck knockout (gckw/–) mice as well as knockout mice treated with insulin or rosiglitazone for 4 weeks are shown. Cristae
density (white arrow) was decreased in the gckw/–mice. Asterisk (*) refers to statistical significance (P < 0.05) in comparisons with gckw/– mice,
while # refers to comparisons with gckw/w mice.
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intervals (Table 3), and MLC2 protein levels (Figure 3) be-
ing restored to wild-type levels, however, LVPW (Table 2)
worsened after treatment with insulin or rosiglitazone.
A significant increase in collagen deposition around
the intramural cardiacvessels and between myofibrils in
heart biopsies from diabetic patients has been found
[31]. The PAS reaction is due to the accumulation of
glycoprotein in the myocardium, which leads to interstitial
fibrosis. Formation of glycoprotein has been suggested to
be due to the increased formation of glucose-derived alde-
hydes, giving rise to so-called advanced glycation end
products (AGEs) [32]. The accumulation of glycoprotein
increases myocardial stiffness by cross-linking. As seen in
our study, reduced gck expression in the liver had an un-
favorable effect on cardiac morphology and lead to the ac-
cumulation of collagen (Masson positive material) and
glycoproteins (PAS positive material) in the myocardium
(Figure 5). Glycoproteins increase intracellular oxidative
stress, which contributes to additional cell damage. Oxida-
tive stress is associated with mitochondrial damage and
plays an important role in the development of diabetic
cardiomyopathy [33].Hyperglycemia-induced impairment of redox balance is
considered to be a key trigger of diabetic complications,
through the up-regulated generation of reactive oxygen
species (ROS) [34], together with an impaired ability of the
endogenous antioxidant defense system to remove them
[35]. The heart is particularly susceptible to oxidative dam-
age, as it possesses lower levels of endogenous antioxidants
in comparison to other organs. Cyba and Cybb are essen-
tial subunits of the NADPH oxidase, an enzyme considered
to be a major source of O2˙
- in cardiac cells catalyzing the
one-electron reduction of oxygen using NADH or NADPH
as the electron donor [36]. Recent evidence suggests that
NADPH oxidase derived superoxide is a key trigger of
mitochondrial dysfunction and up regulated mitochondrial
superoxide generation [37]. SOD is one of the most import-
ant physiological antioxidants against free radicals and
functions to prevent subsequent lipid peroxidation. Lipid
peroxidation, which is a normal phenomenon that occurs
continuously at lowlevels in every individual, is the most
common consequence of oxidative stress. MDA is the end
product of lipid peroxidation and is toxic to cells and cell
membranes. Hyperglycemia contributes to the activation of
free radicals and leads to tissue damage in different organs,
Figure 7 Changes in the protein levels of Insulin signaling pathway in hearts of 60-week old liver-specific gck knockout mice.
Representative Western blots images (A) with quantification of IR (B), PI3K (C), Akt (D), and mTOR (E) from heart homogenates of wild-type
(gckw/w) and gck knockout (gckw/–) mice as well as knockout mice treated with insulin or rosiglitazone for 4 weeks are shown. n = 3 for all
samples. Asterisk (*) refers to statistical significance (P < 0.05 for * and P < 0.001 for ***) in comparisons with gckw/– mice, while # refers to
statistical significance (P < 0.05 for # and P < 0.001 for ###) in comparisons with gckw/w mice.
Li et al. Cardiovascular Diabetology 2014, 13:24 Page 10 of 14
http://www.cardiab.com/content/13/1/24such as endothelial dysfunction, hypertrophy and fibrosis
[38]. In the present study, we found that the MDA content
and Cyba mRNA expression levels were significantly higher
in gckw/– mice than in gckw/w control mice, which is con-
cordant with the finding of significantly decreased SOD ac-
tivity in the gckw/– mice. These results suggest that reduced
liver gck expression may lead to a decreasein the antioxi-
dant capacity of the diabetic myocardium, contributing sig-
nificantly to oxidative stress and the resulting myocardial
damage.
At the same time, our study showed that the mitochon-
drial volume density and number were increased in the
gckw/– mice compared to gckw/w mice (Figure 6). After
treatment with rosiglitazone or insulin, these parameters
were restored to more normal values. Mitochondria are the
center of fatty acid and glucose metabolism and thus are
highly likely to be impacted by impaired metabolism associ-
ated with diabetes. Increased number and size of >mito-
chondria might be an adaptive response to hyperglycemia
[39]. It has recently been shown that insulin resistance
drives the cardiac mitochondrial biogenesis regula-
tory program via PPARα, where activation was increased
due to increased fat uptake and oxidation [40,41]. Theliver-specific glucokinase knockout mouse experienced
long-term hyperglycemia, which results in decreased
insulin receptor levels and ultimately leading to insulin
resistance and attenuated glucose uptake [42]. Insulin re-
sistance drives the cardiac mitochondrial biogenesis regu-
latory program, which lead to increased mitochondrial
volume density and number [43]. Increased oxidative
phosphorlyation and impairment in the electron transport
chain contribute to increased ROS and superoxide (O2˙
-)
production [44]. These changes cause morphological and
functional abnormalities in cardiac tissue, thus suggesting
that oxidative stress might be the unifying factor for the
damaging effects of hyperglycemia [45].
The molecular signaling pathways implicated in myocar-
dial damage in gckw/– mice have not been fully resolved.
We demonstrate that the cardiac insulin receptor and Akt
protein levels, key factors of the IR-PI3K-Akt pathway, were
reduced in gckw/– mice, but were restored to wild-type
levels by insulin or rosiglitazone treatment. The IR-PI3K-
Akt pathway induces a hypertrophic response associated
with cardioprotection [46], in which cardiac structure and
function are preserved. Based on our observations, we pos-
tulate that prolonged exposure to increased levels of serum
Figure 8 Levels of phosphorylated AMPK and ACC in the hearts of 60-week old liver-specific gck knockout mice. Representative Western
blot images (A) and quantification of the levels of p-AMPKα/AMPKα (B), p-AMPKβ/AMPKβ (C), and p-ACC/ACC (D) in heart homogenates of
wild-type (gckw/w) and gck knockout (gckw/–) mice as well as knockout mice treated with insulin or rosiglitazone for 4 weeks are shown.
Phosphorylated AMPK and ACC levels were measured by Western blots. n = 3 for all samples. Asterisk (*) refers to statistical significance (P < 0.05)
in comparisons with gckw/– mice, while # refers to comparisons with gckw/w mice.
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servation of insulin receptor and Akt levels in the
rosiglitazone-treated diabetic myocardium might thereby
confer protection against pathological cardiac hypertrophy.
Metabolic disorders play major roles in the pathogenesis
of diabetic cardiomyopathy. AMPK is a central regulator
for glucose and fatty acid metabolism in mammalian cells,
which acts as anenergy sensor, responding to a rise in AMP
levels by increasing ATP generating pathways and reducing
ATP-consuming pathways [47]. AMPK is a heterotrimeric
complex composed of a catalytic α subunit and regulatory
β and γ subunits. Phosphorylation at Ser108 of theβ1 sub-
unit seems to be required for the activation of AMPKen-
zyme. AMPK phosphorylation inhibits fatty acid and
cholesterol synthesis and gluconeogenesis in the liver and
stimulates fatty acid uptake and oxidation, glucose uptake,
and mitochondrial biogenesis in skeletal muscle [48].ACC is a cytosolic enzyme that catalyzes the carboxyl-
ation of cytosolic acetyl-CoA to form malonyl-CoA, which
is the pivotal step of the fatty acid synthesis pathway [49].
ACCβ is the major isoform in heart. We demonstrated
that the levels of phosphorylated AMPK and ACC were
dramatically lower in gckw/– mice, but only p-ACC was re-
stored to wild-type levels with rosiglitazone treatment. It
has previously been reported that AMPK regulates ACC
phosphorylation [49]. Phosphorylation by AMPK inhibits
the enzymatic activity of ACC, and in turn malonyl-CoA
levels [50]. These results suggest that the fatty acid synthe-
sis pathway may be enhanced in the myocardium of gckw/–
mice, due to a reduction in ACC phosphorylation. The
accumulation of fatty acid also causes a pathological ROS
accumulation, which leads to damage in cardiomyocytes. It
has been hypothesized that the dysregulation of the
AMPK/ACC fuel-sensing and signaling network is a key
Figure 9 The influence of liver-specific glucokinase knockout on the myocardium. The liver-specific glucokinase knockout mouse
experiences long-term hyperglycemia, which induced decreased levels of insulin receptor. Disrupting the early signaling events in the insulin
pathway also has downstream effects on other proteins including Akt and AMPK, ultimately leading to insulin resistance and attenuated glucose
uptake. Fatty acid synthesis increased in cardiomyocyte by decreased AMPK phosphorylation and subsequent increased ACC activity. Increased
glucose stimulates NADPH oxidase expression. NADPH oxidase-derived superoxide generation then contributes to mitochondrial dysfunction,
leading to a further increase in superoxide generation. Insulin resistance, increasing fatty acid synthesis and oxidative stress induced cardiomyocyte
hypertrophy and fibrosis.
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hypertrophy [51].
Conclusions
In conclusion, for the first time, the present study has
established a diabetic cardiomyopathy model using a
liver-specific glucokinase knockout mouse model. The
liver-specific glucokinase knockout mouse experien-
ces long-term hyperglycemia, which induces decreased
levels of insulin receptor. Disrupting the early signaling
events in the insulin pathway also has downstream effects
on other proteins including Akt and AMPK, ultimately
leading to insulin resistance and attenuated glucose up-
take. Fatty acid synthesis increased in cardiomyocyte
by decreased AMPK phosphorylation and subsequent
increased ACC activity. Increased glucose stimulates
NADPH oxidase expression. NADPH oxidase-derived
superoxide generation then contributes to mitochondrial
dysfunction, leading to a further increase in superoxide
generation. Insulin resistance, increasing fatty acid synthe-
sis and oxidative stress induced cardiomyocyte hyper-
trophy and fibrosis (Figure 9). Rosiglitazone treatment
may partly protect against diabetic cardiomyopathy by
modulating cardiac lipid metabolism, oxidative stress and
altering the expression of a set of proteins involved in car-
diac damage, but that myocardial structural and functional
changes cannot be full-reversed in gckw/– mice. Thesefindings suggest that the gckw/– mice may be utilized as an
effective model for research on diabetic cardiomyopathy.
Reduced gck expression in the liver may induce diabetic
cardiomyopathy by up regulating NADPH oxidase and
down regulating insulin receptor and p-AMPK protein
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